Cigna Corp. announced a global workforce reduction of 2,000 employees, to be completed by the end of February. The layoffs span all business units, including its Evernorth specialty‑care and pharmacy‑benefit management segments, and are part of a broader effort to trim operating expenses and strengthen the balance sheet amid rising medical costs.
The announcement follows a strong Q4 2025 earnings report in which Cigna beat consensus estimates, reporting revenue of $72.47 billion—up 3.1% from $70.31 billion in the prior quarter—and adjusted earnings per share of $8.08, a $0.20 beat over the $7.88 consensus. The revenue lift was driven by a 5.2% increase in Evernorth specialty‑pharmacy sales and a 4.5% rise in pharmacy‑benefit management revenue, offsetting a 2.3% decline in the individual‑and‑family‑plan medical care costs that pushed the medical‑care ratio to 88.0%.
Segment analysis shows that Evernorth’s specialty‑pharmacy and care‑services units contributed 12% of total revenue, reflecting strong demand for high‑margin specialty drugs and integrated care models. Cigna Healthcare’s individual‑and‑family‑plan business, while still the largest revenue generator, experienced a modest 1.8% decline in medical‑care costs, largely due to higher stop‑loss and high‑deductible plan expenses. The combination of robust specialty‑pharmacy growth and controlled medical‑care costs enabled the company to maintain a 9.9% operating margin, up from 9.5% in the prior year.
CEO David M. Cordani emphasized that the layoffs are a disciplined response to “unexpectedly high spending on stop‑loss products and general medical costs.” He added that the company is “shifting toward a more efficient, technology‑focused business model” and that the workforce reduction will free up capital for investments in digital health and data analytics. CFO Ann Dennison noted that the company remains “focused on driving greater affordability and value for patients and clients while executing with discipline against its financial targets.”
Cigna’s 2026 guidance maintains a revenue outlook of approximately $280 billion and an adjusted EPS target of at least $30.25, unchanged from the prior guidance. The guidance signals management’s confidence that the cost‑cutting measures, including the workforce reduction, will support margin expansion and sustain earnings growth despite the headwinds of rising medical costs and regulatory scrutiny. The company’s strategic focus on Evernorth’s specialty‑care expansion and the transition to a rebate‑free pharmacy‑benefit model are positioned to offset the short‑term impact of the layoffs and drive long‑term profitability.
The layoffs, while significant, are framed as a necessary step to align Cigna’s operating structure with its long‑term strategy of technology integration and cost discipline. The company’s strong Q4 2025 performance, coupled with a clear guidance outlook, suggests that the workforce reduction will not derail its growth trajectory but rather reinforce its ability to navigate rising medical costs and regulatory changes.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.